Telomir Pharmaceuticals reported asset growth of 546.80% for the quarter ended Jun 2026. These growth metrics cover 13 quarters of results from Mar 2023 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Growth MetricsGrowth | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Growth Ratios | |||||||||||||
| Assets Growth (1y) | 9,696.36% | -72.26% | -85.98% | -60.53% | 610.39% | 454.48% | 546.80% | ||||||
| Assets Growth (3y) | 432.10% | ||||||||||||
| Assets (QoQ) | -26.62% | -40.00% | -50.42% | 27.07% | -62.90% | 68.90% | 792.24% | -0.82% | |||||
| Cash & Equivalents Growth (1y)Cash & Equiv. Growth (1y) | -13.25% | 182,523.13% | 12,887.90% | 33,939.07% | 102,753.86% | -87.79% | -60.30% | 778.14% | 475.51% | 589.36% | |||
| Cash & Equivalents Growth (3y)Cash & Equiv. Growth (3y) | 1,625.24% | 608.37% | |||||||||||
| Cash & Equivalents (QoQ)Cash & Equiv. (QoQ) | 27.34% | 709.57% | -83.24% | -49.80% | 267,974.74% | -42.42% | -56.07% | 51.70% | -68.17% | 87.18% | 871.64% | -0.58% | |
| Cash from Operations Growth (1y)Cash from Ops. Growth (1y) | -163.60% | -4,435.38% | 49.96% | 44.28% | 53.59% | 56.69% | 6.18% | -98.08% | |||||
| Cash from Operations (QoQ)Cash from Ops. (QoQ) | 95.44% | -5,866.18% | 45.73% | -78.38% | 21.48% | 34.18% | 39.56% | -48.56% | 26.71% | -42.58% | -27.60% | ||
| EPS (Basic) Growth (1y) | -1,154.30% | 18.01% | -220.36% | 71.28% | 67.48% | -260.13% | 83.18% | 35.18% | -365.42% | ||||
| EPS (Basic) Growth (3y) | -139.53% | ||||||||||||
| EPS (Basic) (QoQ) | -218.61% | -10.38% | -440.89% | 34.06% | 79.17% | -331.30% | 51.50% | 25.36% | -130.66% | 79.86% | -86.94% | ||
| EPS (Diluted) Growth (1y) | -1,154.30% | 18.01% | -220.36% | 69.47% | 67.48% | -260.13% | 83.18% | 35.18% | -365.42% | ||||
| EPS (Diluted) Growth (3y) | -139.53% | ||||||||||||
| EPS (Diluted) (QoQ) | -218.61% | -10.38% | -408.96% | 29.92% | 79.17% | -331.30% | 51.50% | 25.36% | -130.66% | 79.86% | -86.94% | ||
| FCF Margin Growth (1y) | -299.21M | 0.44M | |||||||||||
| FCF Margin (QoQ) | -0.05M | -298.68M | 299.59M | ||||||||||
| Free Cash Flow Growth (1y)FCF Growth (1y) | -163.60% | -4,435.38% | 49.96% | 44.28% | 53.59% | 56.69% | 6.18% | -98.08% | |||||
| Free Cash Flow (QoQ)FCF (QoQ) | 95.44% | -5,866.18% | 45.73% | -78.38% | 21.48% | 34.18% | 39.56% | -48.56% | 26.71% | -42.58% | -27.60% | ||
| Net Cash Flow Growth (1y)NCF Growth (1y) | 843,478.09% | -10,943.90% | -8,516.83% | 35,439.31% | -127.50% | 52.56% | 725.37% | -109.57% | |||||
| Net Cash Flow (QoQ)NCF (QoQ) | 3,204.64% | -194.97% | 89.97% | 268,165.77% | -142.48% | 24.53% | 141.12% | -308.58% | 26.71% | 1,094.85% | -100.63% | ||
| Net Income Growth (1y) | -1,195.12% | 10.41% | -250.06% | 68.93% | 65.15% | -265.00% | 81.60% | 30.54% | 66.04% | ||||
| Net Income Growth (3y) | -3.55% | ||||||||||||
| Net Income (QoQ) | -221.03% | -10.38% | -445.03% | 32.94% | 77.79% | -331.30% | 51.62% | 24.79% | -132.58% | 78.26% | -82.64% | ||
| Net Income towards Common Stockholders Growth (1y)Net Income Growth (1y) | -1,195.12% | 10.41% | -250.06% | 68.93% | 65.15% | -265.00% | 81.60% | 30.54% | -843.52% | ||||
| Net Income towards Common Stockholders Growth (3y)Net Income Growth (3y) | -213.64% | ||||||||||||
| Net Income towards Common Stockholders (QoQ)Net Income (QoQ) | -221.03% | -10.38% | -445.03% | 32.94% | 77.79% | -331.30% | 51.62% | 24.79% | -132.58% | 78.26% | -82.64% | ||
| Net Margin Growth (1y) | -2,303.95M | 3.63M | |||||||||||
| Net Margin (QoQ) | -3.33M | -2,301.75M | 2,304.25M | ||||||||||
| Revenue Growth (1y) | 100.18% | -99.91% | 186.06% | ||||||||||
| Revenue (QoQ) | 100.59% | -39.41% | -99.72% | 200,727.27% | |||||||||
| Share-based Compensation Growth (1y)Stock Comp. Growth (1y) | -87.40% | ||||||||||||
| Share-based Compensation (QoQ)Stock Comp. (QoQ) | -33.17% | 233.18% | -115.87% |
Pull Telomir Pharmaceuticals's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/statements?ticker=TELO&statement=Growth&frequency=Quarter&period=all&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/statements"
params = {"ticker": "TELO", "statement": "Growth", "frequency": "Quarter", "period": "all", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/statements?ticker=TELO&statement=Growth&frequency=Quarter&period=all&api_key=YOUR_API_KEY");
const data = await res.json();